Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 20, 2026, 6:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 377 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Respiratory Infection Bacterial Clear all
Completed Phase 1 Interventional

Comparison of Two Dosage Regimens of Oral Dapsone for Prophylaxis of Pneumocystis Carinii Pneumonia in Pediatric HIV Infection

NCT00000739
View directory record Official record
Conditions
Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions
Dapsone
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Month to 12 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1998
U.S. locations
43
States / cities
Long Beach, California • Los Angeles, California • Oakland, California + 29 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Sep 20, 2026, 6:47 AM EDT
Completed Phase 3 Interventional

New Antibiotic to Treat Patients With Community-acquired Pneumonia Due to a Specific Bacteria (S. Pneumoniae Pneumonia)

NCT00035269
View directory record Official record
Conditions
Pneumonia, Pneumococcal, Community Acquired Infections, Gram-positive Bacterial Infections
Interventions
Antibiotic
Drug
Lead sponsor
Pfizer
Industry
Eligibility
13 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
34
States / cities
Los Angeles, California • Jacksonville, Florida • Naples, Florida + 29 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2011 · Synced Sep 20, 2026, 6:47 AM EDT
Completed Phase 4 Interventional

Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Complicated Community Acquired Pneumonia (CABP)

NCT01669980
View directory record Official record
Conditions
Infections, Pneumonia
Interventions
Ceftaroline fosamil, IV Ceftriaxone and Vancomycin
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
2 Months to 18 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
13
States / cities
Long Beach, California • Oakland, California • Orange County, California + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2015 · Synced Sep 20, 2026, 6:47 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis (CF) Patients With Pseudomonas Aeruginosa (PA)

NCT00128492
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
AZLI 75 mg two times a day (BID)/ three times a day (TID)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
6 Years and older
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
56
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated May 18, 2011 · Synced Sep 20, 2026, 6:47 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age

NCT01659996
View directory record Official record
Conditions
Meningitis, Meningococcal Infection, Diphtheria, Tetanus, Pertussis, Haemophilus Influenzae Serotype b (Hib)
Interventions
Meningococcal polysaccharide diphtheria toxoid conjugate, Meningococcal polysaccharide diphtheria toxoid conjugate + Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
9 Months to 18 Months
Enrollment
1,394 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
56
States / cities
Birmingham, Alabama • Pinson, Alabama • Tucson, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2015 · Synced Sep 20, 2026, 6:47 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Trial to Evaluate the Safety and Immunogenicity of ADACEL® Vaccine in Persons 65 Years of Age and Older

NCT00457249
View directory record Official record
Conditions
Pertussis, Tetanus, Diphtheria
Interventions
ADACEL®: Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed, DECAVAC®: Tetanus and Diphtheria Toxoids Adsorbed
Biological
Lead sponsor
Sanofi
Industry
Eligibility
65 Years and older
Enrollment
1,564 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
19
States / cities
Chandler, Arizona • Phoenix, Arizona • Cypress, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2012 · Synced Sep 20, 2026, 6:47 AM EDT
Completed Phase 3 Interventional Results available

Comparative Study of Ceftaroline vs. Ceftriaxone in Adult Subjects With Community-Acquired Pneumonia

NCT00621504
View directory record Official record
Conditions
Bacterial Pneumonia
Interventions
Ceftaroline fosamil for Injection, IV Ceftriaxone, Placebo, Clarithromycin
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
606 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
12
States / cities
Los Angeles, California • Pasadena, California • Sacramento, California + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Sep 20, 2026, 6:47 AM EDT
Completed Phase 3 Interventional

The Treatment of Tuberculosis in HIV-Infected Patients

NCT00001033
View directory record Official record
Conditions
HIV Infections, Tuberculosis
Interventions
Ethambutol hydrochloride, Isoniazid, Pyrazinamide, Pyridoxine hydrochloride, Levofloxacin, Rifampin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1997
U.S. locations
12
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Sep 20, 2026, 6:47 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease

NCT00855855
View directory record Official record
Conditions
Haemophilus Infections, Diphtheria, Tetanus, Polio, Pertussis
Interventions
DTaP-IPV/Hib
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
Up to 59 Months
Enrollment
20,830 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
59
States / cities
Albany, California • Martinez, California • San Francisco, California + 56 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2022 · Synced Sep 20, 2026, 6:47 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®

NCT00355121
View directory record Official record
Conditions
Meningococcal Meningitis, Tetanus, Diphtheria, Pertussis, Poliomyelitis
Interventions
Polysaccharide Diphtheria Toxoid Conjugate Vaccine
Biological
Lead sponsor
Sanofi
Industry
Eligibility
4 Years to 7 Years
Enrollment
882 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
26
States / cities
Little Rock, Arkansas • Boulder, Colorado • Atlanta, Georgia + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2011 · Synced Sep 20, 2026, 6:47 AM EDT
Completed Phase 3 Interventional

A Randomized, Comparative Study of Daily Dapsone and Daily Atovaquone for Prophylaxis Against PCP in HIV-Infected Patients Who Are Intolerant of Trimethoprim and/or Sulfonamides

NCT00000802
View directory record Official record
Conditions
Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions
Atovaquone, Dapsone
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1997
U.S. locations
43
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 30 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Sep 20, 2026, 6:47 AM EDT
Completed Phase 4 Interventional

Effectiveness of Short-Course Versus Standard Antibiotic Therapy in ICU Patients

NCT00410527
View directory record Official record
Conditions
Bacterial Infections
Interventions
Merrem
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
12
States / cities
Birmingham, Alabama • Newark, Delaware • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 20, 2026, 6:47 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. Aeruginosa

NCT00104520
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
AZLI 75 mg two times a day (BID)/three times a day (TID), Placebo two times a day (BID)/three times a day (TID)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
6 Years and older
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
56
States / cities
Phoenix, Arizona • Little Rock, Arkansas • La Jolla, California + 50 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2011 · Synced Sep 20, 2026, 6:47 AM EDT
Completed No phase listed Observational

MASTERMIND-Pneumonia Study (Also Known as Pneumonia Direct Pilot)

NCT06181669
View directory record Official record
Conditions
Pneumonia, Bacterial, Ventilator Associated Pneumonia
Interventions
Pathogen and Host Directed testing
Diagnostic Test
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
4
States / cities
Detroit, Michigan • Royal Oak, Michigan • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced Sep 20, 2026, 6:47 AM EDT
Completed Phase 3 Interventional Results available

Clinical Study of Cefiderocol (S-649266) for the Treatment of Nosocomial Pneumonia Caused by Gram-negative Pathogens

NCT03032380
View directory record Official record
Conditions
Healthcare-associated Pneumonia (HCAP), Hospital Acquired Pneumonia (HAP), Ventilator Associated Pneumonia (VAP)
Interventions
Cefiderocol, Meropenem, Linezolid
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
15
States / cities
New Haven, Connecticut • DeLand, Florida • Chicago, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2020 · Synced Sep 20, 2026, 6:47 AM EDT
Completed No phase listed Observational

Early Molecular Detection for the Improved Diagnosis of Invasive Pulmonary Aspergillosis and Invasive Pulmonary Zygomycosis

NCT00923832
View directory record Official record
Conditions
Immunocompromised Host, Invasive Pulmonary Fungal Infection, Invasive Pulmonary Aspergillosis, Invasive Pulmonary Zygomycosis
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 20, 2026, 6:47 AM EDT
Completed Phase 2Phase 3 Interventional

Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Community Acquired Bacterial Pneumonia (CABP)

NCT01530763
View directory record Official record
Conditions
Infections, Community Acquired Pneumonia
Interventions
Ceftaroline fosamil, Ceftriaxone, amoxicillin clavulanate
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
2 Months to 18 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
13
States / cities
Long Beach, California • Oakland, California • Orange, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2015 · Synced Sep 20, 2026, 6:47 AM EDT
Completed No phase listed Observational

A Study of Psychosocial and Behavioral Determinants of Differential Rates of Participant Compliance in CPCRA Protocols

NCT00000784
View directory record Official record
Conditions
Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
557 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 1996
U.S. locations
13
States / cities
Denver, Colorado • Wilmington, Delaware • Washington D.C., District of Columbia + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2013 · Synced Sep 20, 2026, 6:47 AM EDT
Completed Phase 2 Interventional Results available

A Study Of Intravenous Sulopenem And Oral PF-03709270 In Community Acquired Pneumonia That Requires Hospitalization

NCT00797108
View directory record Official record
Conditions
Pneumonia, Bacterial
Interventions
Sulopenem and PF-03709270, Ceftriaxone and amoxicillin/clavulanate
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
12
States / cities
Chula Vista, California • Oceanside, California • Moline, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2016 · Synced Sep 20, 2026, 6:47 AM EDT
Completed No phase listed Observational Results available

A Study To Learn About The Effects Of Pneumococcal Vaccine In People With HIV

NCT05794191
View directory record Official record
Conditions
HIV, Pneumonia, Infections, Pneumococcal
Interventions
Vaccine Administration
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
350,399 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 19, 2025 · Synced Sep 20, 2026, 6:47 AM EDT
Recruiting Phase 2 Interventional

Phase 2a Multiple Ascending Dose Study in Hospitalized Patients With Pneumonia.

NCT05123755
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Viral or Bacterial Infections, Pneumonia, Pneumonia, Viral, Respiratory Infection, COVID-19 Acute Respiratory Distress Syndrome
Interventions
AV-001 Injection, AV-001 Placebo Injection
Drug
Lead sponsor
Vasomune Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
5
States / cities
Newport Beach, California • Denver, Colorado • Hyattsville, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 20, 2026, 6:47 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Vouchers to Promote Tdap Vaccination

NCT01860378
View directory record Official record
Conditions
Whooping Cough
Interventions
Full price, $5 off
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
18 Years and older
Enrollment
149 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 2, 2015 · Synced Sep 20, 2026, 6:47 AM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age

NCT07365826
View directory record Official record
Conditions
Pneumococcal Vaccines
Interventions
31-valent pneumococcal conjugate vaccine, Seasonal Influenza Vaccine (SIV) (Flublok), Placebo
Biological
Lead sponsor
Vaxcyte, Inc.
Industry
Eligibility
50 Years and older
Enrollment
1,390 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
25
States / cities
Phoenix, Arizona • Fort Collins, Colorado • DeLand, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 20, 2026, 6:47 AM EDT
Completed Not applicable Interventional Results available

System Alignment for VaccinE Delivery (SAVED): Improving Rates of Influenza and Pneumococcal Vaccination Through Patient Outreach, Improved Medical Record Accuracy and Targeted Physician Alerts

NCT02266277
View directory record Official record
Conditions
Influenza, Infections, Pneumococcal
Interventions
Arm 1: E-portal message with IVR call, Arm 2: E-portal message with no IVR call, Arm 3: No e-portal message with IVR call, Arm 5: IVR call
Other
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older
Enrollment
30,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Sep 20, 2026, 6:47 AM EDT